Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene Laherparepvec in Peritoneal Surface Malignancies
NCT03663712Phase 1Completed
- Start
- May 2019
- Primary completion
- Oct 2022
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of talimogene laherparepvec in Peritoneal surface malignancies (PSM) (3 arms). Primary endpoint: Dose Limiting Toxicity up to 14 weeks. Started May 2019; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
Peritoneal surface malignancies (PSM)
Beyond the preview
Go deeper on NCT03663712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03663712.